supplied by www.ccc.ac.at

2 Einträge

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Autoren Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A
Erscheinungsdaten The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9
Publikations ID PMID: 29146401
 


Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: Pan-European non-interventional study.
Autoren Steger G, Pichler P, Airoldi M, Mazza P, Fontaine C, Timmer Bonte J, Walewski JA, Katolicka J, Mikulova M, Gasparic M
Erscheinungsdaten Annals of oncology : official journal of the European Society for Medical Oncology. pii: S0923-7534(19)50139-9. doi: 10.1093/annonc/mdy300.014
Publikations ID PMID: 32137621